Antiparasitic agent-38
Antiparasitic agent-38 is an orally active antischistosomal agent that effectively clears Schistosoma mansoni infections in mice (single oral LD50=0.8 g/kg) and significantly inhibits S. mansoni infection. Antiparasitic agent-38 can be used for research on schistosomiasis, particularly S. mansoni infection .
For research use only. We do not sell to patients.
- CAS No.: 15382-63-5
- Formula: C14H23NO2
- Molecular Weight:237.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Parasite Isoforms
More
Biological Activity
Description
IC50 & Target
|
Schistosome |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (infected with adult Schistosoma mansoni)[1]
-
Dosage:LD50/16 (0.05 g/kg) per day
-
Administration:p.o.; daily; 4 days
-
Result:Achieved 25–75% cure rate; had an approximate single-dose LD50 of 0.8 g/kg.
Significantly reduced the number of free worms recovered from the mesenteric veins, portal vein, and liver of infected mice.
Chemical Information
-
CAS No. 15382-63-5
-
Molecular Weight 237.34
-
Formula C14H23NO2
-
SMILES
O(C1=CC(N)=CC=C1OCCCCCCC)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)